BI X hopes start-up spirit will take root in Rhineland

In a previous incarnation, Boehringer Ingelheim chief financial officer Michael Schmelmer spearheaded a bold approach to innovation which could bear digital fruit for the 130 year-old family-owned drugmaker.

As chief information officer, a role he left in March 2018, he led the establishment of the firm’s innovation hub, BI X, based in a refurbished cluster of low-lying buildings that formerly housed a casino for guests at the firm’s sprawling campus in Ingelheim.

Tasked with bringing forward new and potentially disruptive platforms, engineers at BI X must pass a simple test to proceed: convince the “digital board” with a simple five-minute presentation, followed by five minutes for follow up questions.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical